Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Selvaggi

Nurse Practitioner, Primary Care Lakewood Ranch, FL Nurse Practitioner

NPI 1275918385 CMS profile 11073245

6771 Professional Pkwy Ste 203, Lakewood Ranch, FL 34240

Open in the dashboard

General payments

$10,240

459 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Selvaggi of Lakewood Ranch, FL is reported in the CMS Open Payments database as having received $10,240 across 459 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,658 118
2024 General $2,740 101
2023 General $1,428 66
2022 General $1,345 72
2021 General $2,070 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Selvaggi
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Michelle Selvaggi were reported at $2,658. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Michelle Selvaggi Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,070 $137 $39–$445 $132
2022 $1,345 $139 $44–$421 $149
2023 $1,428 $163 $53–$481 $160
2024 $2,740 $176 $54–$511 $164
2025 $2,658 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,803 86 payments
  2. Sun Pharmaceutical Industries Inc. $1,077 62 payments
  3. Novartis Pharmaceuticals Corporation $915 49 payments
  4. Janssen Biotech, Inc. $765 32 payments
  5. Genzyme Corporation $613 23 payments
  6. Incyte Corporation $531 25 payments
  7. Regeneron Healthcare Solutions, Inc. $485 22 payments
  8. UCB, Inc. $461 13 payments
  9. Revance Therapeutics, Inc. $411 4 payments
  10. LEO Pharma Inc. $408 17 payments
  11. Other $2,772 126 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,870 454 payments
  2. Education $370 5 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $889 31 payments
  2. TREMFYA $853 29 payments
  3. RINVOQ $757 34 payments
  4. ILUMYA $694 32 payments
  5. SKYRIZI Immunology $587 30 payments
  6. OPZELURA $531 25 payments
  7. COSENTYX Dermatology $419 20 payments
  8. SKYRIZI Immunology $379 17 payments
  9. COSENTYX Immunology $367 23 payments
  10. Bimzelx $358 9 payments
  11. Other $5,918 291 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

261

Median for Nurse Practitioner: 389

Drug cost

$60,976

Median for Nurse Practitioner: $21,885

Branded share of claims

11.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 15 $55,268
Betamethasone Dipropionate Generic 47 $1,860
Ketoconazole Generic 56 $1,011
Fluorouracil Generic 11 $843
Clobetasol Propionate Generic 14 $626
Triamcinolone Acetonide Generic 51 $522
Valacyclovir Valacyclovir Hcl Brand 14 $391
Doxycycline Hyclate Generic 25 $270
Mupirocin Generic 28 $185

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$96,870

Of which drugs: $57,393

Medicare patients

240

Average age 75

Services billed

1,402

134 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 57%
Ischemic heart disease 33%
Atrial fibrillation 20%
Diabetes 19%
Cancer 19%
Chronic kidney disease 18%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $211
  • Regeneron Healthcare Solutions, Inc. $63
$274 15 —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $265
$265 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $253
$253 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $210
$210 — —
OPZELURA
  • Incyte Corporation $206
$206 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

459 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record